Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2rg^null RIP-DTR mice engrafted with human islets

References

• DruckerDJGlucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosisMol Endocrinol2003172161 17112554744
   PubMed Web of Science ®Google Scholar
• GarberAJIncretin effects on beta-cell function, replication, and mass: the human perspectiveDiabetes Care201134Suppl 2S258 S26321525465
   PubMed Web of Science ®Google Scholar
• KwonDYKimYSAhnISExendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic ratsJ Pharmacol Sci20091114361 37120019445
   PubMed Web of Science ®Google Scholar
• BrubakerPLDruckerDJMinireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous systemEndocrinology200414562653 265915044356
   PubMed Web of Science ®Google Scholar
• EganJMBulottaAHuiHPerfettiRGLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes Metab Res Rev2003192115 12312673779
   PubMed Web of Science ®Google Scholar
• PerfettiRMerkelPGlucagon-like peptide-1: a major regulator of pancreatic beta-cell functionEur J Endocrinol20001436717 72511124853
   PubMed Web of Science ®Google Scholar
• YamaneSHamamotoYHarashimaSGLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated beta-cell damage in Akita miceJ Diabetes Investig201122104 110
   Web of Science ®Google Scholar
• YustaBBaggioLLEstallJLGLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stressCell Metab200645391 40617084712
   PubMed Web of Science ®Google Scholar
• TsunekawaSYamamotoNTsukamotoKProtection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studiesJ Endocrinol2007193165 7417400804
   PubMed Web of Science ®Google Scholar
• FehseFTrautmannMHolstJJExenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab200590115991 599716144950
   PubMed Web of Science ®Google Scholar
• VilsbollTZdravkovicMLe-ThiTLiraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetesDiabetes Care20073061608 161017372153
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMBehleKEffects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteersJ Clin Endocrinol Metab20028731239 124611889194
   PubMed Web of Science ®Google Scholar
• RotherKISpainLMWesleyRAEffects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetesDiabetes Care200932122251 225719808924
   PubMed Web of Science ®Google Scholar
• SarkarGAlattarMBrownRJExenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetesDiabetes Care2014373666 67024194508
   PubMed Web of Science ®Google Scholar
• ElkinsonSKeatingGMLixisenatide: first global approvalDrugs2013734383 39123558600
   PubMed Web of Science ®Google Scholar
• PetersenABKnopFKChristensenMLixisenatide for the treatment of type 2 diabetesDrugs Today (Barc)2013499537 55324086950
   PubMed Web of Science ®Google Scholar
• ChristensenMKnopFKHolstJJVilsbollTLixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitusIDrugs2009128503 51319629885
   PubMed Web of Science ®Google Scholar
• WernerUHaschkeGHerlingAWKramerWPharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetesRegul Pept20101642–358 6420570597
   PubMedGoogle Scholar
• FonsecaVAAlvarado-RuizRRaccahDBokaGMiossecPGerichJEEfficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Diabetes Care20123561225 123122432104
   PubMed Web of Science ®Google Scholar
• HorowitzMRaynerCKJonesKLMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetesAdv Ther201330281 10123423907
   PubMed Web of Science ®Google Scholar
• PetersenABChristensenMClinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusDiabetes Metab Syndr Obes20136217 23123825925
   PubMedGoogle Scholar
• AhrenBGautierJFBerriaRStagerWAronsonRBaileyCJPronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2014169861 86824641271
   PubMed Web of Science ®Google Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol2012812728 74222945360
   PubMed Web of Science ®Google Scholar
• CerveraAWajcbergESriwijitkamolAMechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAm J Physiol Endocrinol Metab20082945E846 E85218334612
   PubMed Web of Science ®Google Scholar
• LinnebjergHParkSKotharePAEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesRegul Pept20081511–3123 12918675854
   PubMedGoogle Scholar
• TewsDWernerUEckelJEnhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analoguesHorm Metab Res2008403172 18018348079
   PubMed Web of Science ®Google Scholar
• ShultzLDIshikawaFGreinerDLHumanized mice in translational biomedical researchNat Rev Immunol200772118 13017259968
   PubMed Web of Science ®Google Scholar
• ShultzLDLyonsBLBurzenskiLMHuman lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cellsJ Immunol2005174106477 648915879151
   PubMed Web of Science ®Google Scholar
• JurczykADiiorioPBrostowinDImproved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rgamma(null) mice treated with alogliptinDiabetes Metab Syndr Obes20136493 49924376359
   PubMedGoogle Scholar
• PerlSKushnerJABuchholzBASignificant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon datingJ Clin Endocrinol Metab20109510E234 E23920660050
   PubMed Web of Science ®Google Scholar
• LevittHECyphertTJPascoeJLGlucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) miceDiabetologia2011543572 58220936253
   PubMed Web of Science ®Google Scholar
• DiiorioPJurczykAYangCHyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rgammanull Ins2Akita micePancreas20114071147 114921926555
   PubMed Web of Science ®Google Scholar
• BrissovaMFowlerMJNicholsonWEAssessment of human pancreatic islet architecture and composition by laser scanning confocal microscopyJ Histochem Cytochem20055391087 109715923354
   PubMed Web of Science ®Google Scholar
• BeckerRHStechlJMsihidJKapitzaCLixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjectsDiabetes Obes Metab2014169793 80024521245
   PubMed Web of Science ®Google Scholar
• RatnerRERosenstockJBokaGInvestigatorsDRISDose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trialDiabet Med20102791024 103220722676
   PubMed Web of Science ®Google Scholar
• FarillaLBulottaAHirshbergBGlucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human isletsEndocrinology2003144125149 515812960095
   PubMed Web of Science ®Google Scholar
• BiarnesMMontolioMNacherVRaurellMSolerJMontanyaEBeta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemiaDiabetes200251166 7211756324
   PubMed Web of Science ®Google Scholar
• DavalliAMOgawaYRicordiCScharpDWBonner-WeirSWeirGCA selective decrease in the beta cell mass of human islets transplanted into diabetic nude miceTransplantation1995596817 8207701574
   PubMed Web of Science ®Google Scholar
• ToyodaKOkitsuTYamaneSGLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosisBiochem Biophys Res Commun20083674793 79818211828
   PubMed Web of Science ®Google Scholar